Tycho Baumann
YOU?
Author Swipe
View article: Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics
Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics Open
Circulating tumor DNA (ctDNA) is a valuable prognostic biomarker in follicular lymphoma (FL) frontline treatment, providing a minimally invasive tool to monitor disease. However, its prognostic value in the relapsed or refractory (R/R) set…
View article: First Case of Tap1 Deficiency With Ebv B-cell Lymphoma Treated With Cellular Immunotherapy
First Case of Tap1 Deficiency With Ebv B-cell Lymphoma Treated With Cellular Immunotherapy Open
Purpose: Bare Lymphocyte Syndrome (BLS) type I, due to mutations in TAP1, leads to impaired HLA class I expression and increased susceptibility to infections. EBV-driven lymphomas are rare in BLS patients. Here, we will expose the manageme…
View article: Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma
Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma Open
Background/Objectives: This study aimed to determine whether interim PET/CT (iPET) scans could identify follicular lymphoma (FL) patients at high risk of relapse following first-line therapy. Methods: A total of 117 FL patients who underwe…
View article: Interim PET/CT Evaluation in First-Line Follicular Lymphoma
Interim PET/CT Evaluation in First-Line Follicular Lymphoma Open
Background/Objectives: This study aimed to determine whether interim PET/CT (iP-ET) scans could identify follicular lymphoma (FL) patients at high risk of relapse fol-lowing first-line therapy. Additionally, the potential of cell-free DNA …
View article: The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study
The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study Open
Background: Assessment of bone marrow infiltration (BMI) is part of the initial staging of mantle cell lymphoma (MCL), although BMI evaluated by biopsy (BMB) is not considered significant in the MIPI scales, and standardized recommendation…
View article: Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL
Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL Open
Testicular large B‐cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune‐privileged site and has recently been recognized as a distinct entity from diffuse large B‐cell lymphoma (DLBCL). We describe the geneti…
View article: Blastic Plasmacytoid Dendritic Cell Neoplasm: A Single-Center Experience. Clinical Characterization, Mutational Landscape, and Clinical Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation Intensive Therapy
Blastic Plasmacytoid Dendritic Cell Neoplasm: A Single-Center Experience. Clinical Characterization, Mutational Landscape, and Clinical Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation Intensive Therapy Open
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematodermic neoplasm usually involving the skin. In this retrospective case series, 10 cases of BPDCN were identified, 90% of which had skin involvement and exh…
View article: Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients Open
[This corrects the article DOI: 10.3389/fimmu.2023.1188818.].
View article: Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients Open
[This corrects the article DOI: 10.3389/fimmu.2023.1188818.].
View article: P1100: PET INTERIM RESULTS COULD PROMPTLY SELECT FOLLICULAR LYMPHOMA PATIENTS IN NEED OF MAINTENANCE THERAPY. POTENTIAL ADDITIONAL VALUE OF CFDNA.
P1100: PET INTERIM RESULTS COULD PROMPTLY SELECT FOLLICULAR LYMPHOMA PATIENTS IN NEED OF MAINTENANCE THERAPY. POTENTIAL ADDITIONAL VALUE OF CFDNA. Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Follicular Lymphoma (FL) patients frequently achieve long remissions with frontline chemoimmunotherapy (CIT); nevertheless, a subset of patients will experienc…
View article: IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia Open
Chronic lymphocytic leukemia (CLL) has high biological and clinical heterogeneity.1,2 A few prognostic factors are used in clinical practice, including immunoglobulin heavy-chain variable (IGHV) gene somatic hypermutation (SHM) status, chr…
View article: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients Open
Background CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores the potential value of ctDNA…
View article: PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNA
PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNA Open
Background: Follicular Lymphoma (FL) patients frequently achieve long remissions with frontline chemoimmunotherapy (CIT); nevertheless, a subset of patients will experience early progression and a poor outcome. Fluoro-[18F]-deoxy-2-D-gluco…
View article: Sup Tables 1-6 from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Sup Tables 1-6 from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Open
Supplementary Table S1. 782 genes identified by piggyBac transposon mutagensis in HG3 cell line after fludarabine selection Supplementary Table S2. Gene Symbol/Gene Description Supplementary Table S3A. Molecular characteristics of BRAF mut…
View article: Supplementary Figures S1-8 from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Supplementary Figures S1-8 from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Open
Supplementary Figure S1. schematic illustration of piggyBac transposon and transposase vectors used. PB IR refers to piggyBac inverted repeats. FRT is flippase recognition target. Supplementary Figure S2. Real-time quantitative PCR analysi…
View article: Data from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Data from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Open
Purpose: To identify resistance mechanisms for the chemotherapeutic drug fludarabine in chronic lymphocytic leukemia (CLL), as innate and acquired resistance to fludarabine-based chemotherapy represents a major challenge for long-term dise…
View article: Data from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Data from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study Open
Purpose:We analyzed the utility of cell-free DNA (cfDNA) in a prospective population-based cohort to determine the mutational profile, assess tumor burden, and estimate its impact in response rate and outcome in patients with diffuse large…
View article: Supplemental Material from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Supplemental Material from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study Open
Suppplementary Methods and Figures
View article: Supplementary Material and Methods from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Supplementary Material and Methods from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Open
Supplementary Material and Methods in Word format
View article: Data from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Data from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Open
Purpose: To identify resistance mechanisms for the chemotherapeutic drug fludarabine in chronic lymphocytic leukemia (CLL), as innate and acquired resistance to fludarabine-based chemotherapy represents a major challenge for long-term dise…
View article: Supplementary Material and Methods from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Supplementary Material and Methods from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Open
Supplementary Material and Methods in Word format
View article: Data from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Data from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study Open
Purpose:We analyzed the utility of cell-free DNA (cfDNA) in a prospective population-based cohort to determine the mutational profile, assess tumor burden, and estimate its impact in response rate and outcome in patients with diffuse large…
View article: Supplementary tables from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Supplementary tables from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study Open
Supplementary tables S1 to S6
View article: supplemental figure and table legend from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
supplemental figure and table legend from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Open
supplemental figure and table legend